Literature DB >> 20860031

Regulation of the 5-HT3A receptor-mediated current by alkyl 4-hydroxybenzoates isolated from the seeds of Nelumbo nucifera.

Ui Joung Youn1, Jun-Ho Lee, Yoo Jin Lee, Joo Won Nam, Hyunsu Bae, Eun-Kyoung Seo.   

Abstract

Four known alkyl 4-hydroxybenzoates, i.e., methyl 4-hydroxybenzoate (1), ethyl 4-hydroxybenzoate (2), propyl 4-hydroxybenzoate (3), and butyl 4-hydroxybenzoate (4), were isolated from the seeds of Nelumbo nucifera Gaertner (Nymphaeaceae) for the first time. The structures of the isolates were identified by 1D- and 2D-NMR spectroscopy and comparison with published values. The compounds were evaluated for their effects on the 5-HT-stimulated inward current (I(5-HT)) mediated by the human 5-HT(3)A receptors expressed in Xenopus oocytes. Compounds 1 and 2 enhanced the I(5-HT), but 4 reduced it. These results indicate that 4 is an inhibitor of the 5-HT(3)A receptors expressed in Xenopus oocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20860031     DOI: 10.1002/cbdv.200900393

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN: 1612-1872            Impact factor:   2.408


  3 in total

1.  Rapid-Onset Antidepressant-Like Effect of Nelumbinis semen in Social Hierarchy Stress Model of Depression.

Authors:  Jihwan Shin; Jeonghun Lee; Junhyuk Choi; Byung-Taek Ahn; Sang Chul Jang; Seung-Won You; Do-Yeon Koh; Sungho Maeng; Seung-Yun Cha
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-29       Impact factor: 2.650

2.  Assessment of anti-depressant effect of nelumbinis semen on rats under chronic mild stress and its subchronic oral toxicity in rats and beagle dogs.

Authors:  Hwan-Suck Chung; Hye Jeong Lee; Insop Shim; Hyunsu Bae
Journal:  BMC Complement Altern Med       Date:  2012-05-28       Impact factor: 3.659

3.  Effect of Nelumbo nucifera Petal Extracts on Lipase, Adipogenesis, Adipolysis, and Central Receptors of Obesity.

Authors:  Chandrasekaran Chinampudur Velusami; Amit Agarwal; Vijayalakshmi Mookambeswaran
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-14       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.